Valuation : SCYNEXIS, Inc.

Market Cap 5.14Cr 4.44Cr 4.17Cr 3.8Cr 7.15Cr 488.19Cr 7.19Cr 49Cr 19Cr 248.33Cr 19Cr 19Cr 823.43Cr P/E 2026 *
-1.78x
P/E 2027 * -2.23x
Enterprise Value 5.14Cr 4.44Cr 4.17Cr 3.8Cr 7.15Cr 488.19Cr 7.19Cr 49Cr 19Cr 248.33Cr 19Cr 19Cr 823.43Cr EV / Sales 2026 *
83x
EV / Sales 2027 * 7.7x
Free-Float
98%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : SCYNEXIS, Inc.

1 day+1.06%
1 week-8.11%
Current month-0.38%
1 month+2.76%
3 months+2.16%
6 months-13.09%
Current year+2.98%
1 week 5.11
Extreme 5.11
5.7
1 month 4.41
Extreme 4.41
6.09
Current year 3.53
Extreme 3.53
9.12
1 year 3.53
Extreme 3.53
10.48
3 years 3.53
Extreme 3.53
30.96
5 years 3.53
Extreme 3.53
64.8
10 years 3.53
Extreme 3.53
440.8
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2023
Director of Finance/CFO 65 24/10/2022
Chief Tech/Sci/R&D Officer - 01/10/2020
Director TitleAgeSince
Director/Board Member 73 01/12/2008
Chairman 67 04/06/2015
Director/Board Member 61 01/01/2023
Date Insider Type Main position Quantity % Market Cap. Importance
01/04/26 Buy

Chief Executive Officer

2,17,390 0.2736%
29/01/26 Free

Chief Financial Officer

1,29,833 0.3094%
29/01/26 Free

Chief Executive Officer

3,91,333 0.9325%
Change 5-day change 1-year change 3-year change Capi.($)
+0.77%-8.11%-22.05%-81.18% 5.14Cr
+0.25%-1.87%+58.76%+109.11% 1,03400Cr
+0.88%+1.53%+53.96%+70.61% 65TCr
-0.68%-1.78%+21.85%+76.75% 46TCr
+0.49%-5.19%+33.28%+35.53% 34TCr
+0.27%+3.26%+29.76%+47.50% 31TCr
+0.12%-2.11%+0.60%+12.03% 25TCr
-0.68%-0.99%+51.96%+71.64% 24TCr
+2.64%-1.08%-15.85%-53.97% 20TCr
-0.69%+0.90%+32.58%+98.82% 19TCr
Average +0.39%-2.63%+24.49%+38.68% 36.72TCr
Weighted average by Cap. +0.33%-3.31%+38.65%+67.66%

Financials

2026 *2027 *
Net sales 6L 5L 5L 5L 9L 5.88Cr 9L 59.43L 23.13L 2.99Cr 23.26L 22.75L 9.92Cr 66.77L 57.6L 54.18L 49.36L 92.82L 63Cr 93.32L 6.41Cr 2.49Cr 32Cr 2.51Cr 2.45Cr 106.89Cr
Net income -3.06Cr -2.64Cr -2.48Cr -2.26Cr -4.25Cr -289.94Cr -4.27Cr -29Cr -11Cr -147.49Cr -11Cr -11Cr -489.04Cr -3.24Cr -2.8Cr -2.63Cr -2.4Cr -4.51Cr -307.78Cr -4.53Cr -31Cr -12Cr -156.56Cr -12Cr -12Cr -519.13Cr
Net Debt - -
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
02/26/02 $5.210 +0.77% 8,454
01/26/01 $5.170 -1.15% 76,079
31/26/31 $5.230 -2.97% 42,370
28/26/28 $5.390 -2.36% 56,835
27/26/27 $5.520 -2.65% 87,201
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.170USD
Average target price
36.55USD
Spread / Average Target
+606.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCYX Stock